Valeant Pharms Company Profile

What is the competitive landscape for VALEANT PHARMS

VALEANT PHARMS has nineteen approved drugs.

There are six US patents protecting VALEANT PHARMS drugs.

There are forty-four patent family members on VALEANT PHARMS drugs in twelve countries and nineteen supplementary protection certificates in thirteen countries.

Summary for Valeant Pharms

International Patents:	44
US Patents:	6
Tradenames:	14
Ingredients:	12
NDAs:	19

Drugs and US Patents for Valeant Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharms Intl	GIAZO	balsalazide disodium	TABLET;ORAL	022205-001	Feb 3, 2012		DISCN	Yes	No	9,192,616
Valeant Pharms North	SECONAL SODIUM	secobarbital sodium	CAPSULE;ORAL	086101-001	Oct 3, 1983		DISCN	No	No
Valeant Pharms North	SECONAL SODIUM	secobarbital sodium	CAPSULE;ORAL	086101-002	Oct 3, 1983		DISCN	No	No
Valeant Pharms North	RETIN-A	tretinoin	CREAM;TOPICAL	017340-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

Expired US Patents for Valeant Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Valeant Pharms Intl	GIAZO	balsalazide disodium	TABLET;ORAL	022205-001	Feb 3, 2012	6,197,341
Valeant Pharms	ULTRAM ER	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021692-002	Sep 8, 2005	6,254,887
Valeant Pharms	ULTRAM ER	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021692-001	Sep 8, 2005	6,254,887
Valeant Pharms North	RENOVA	tretinoin	CREAM;TOPICAL	021108-001	Aug 31, 2000	6,531,141

Paragraph IV (Patent) Challenges for VALEANT PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	100 mg		2007-01-08
	Extended-release Tablets	300 mg		2007-09-25
	Extended-release Tablets	200 mg		2007-03-28
	Tablets	1.1 g		2013-11-05

International Patents for Valeant Pharms Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2007025146
China	105267226
Canada	3004028
European Patent Office	2096912

Supplementary Protection Certificates for Valeant Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0617614	2001/009	Ireland		PRODUCT NAME: PANRETIN-ALITRETINOIN
1304992	122013000081	Germany		PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322
1304992	132013902214376	Italy		PRODUCT NAME: CLINDAMICINA FOSFATO E TRETINOINA(ACNATAC); AUTHORISATION NUMBER(S) AND DATE(S): PA1332/043/001, 20130322;042056010/M - 022/M, 20130718
1304992	SPC/GB13/061	United Kingdom		PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Vale
• Valeant
• Valeant Bermuda
• Valeant Intl

Pharmaceutical Competitive Landscape Analysis: Valeant Pharmaceuticals – Market Position, Strengths & Strategic Insights

Last updated: January 25, 2026

Summary

Valeant Pharmaceuticals, now rebranded as Bausch Health Companies Inc., is a major player in the pharmaceutical and healthcare industry. Its repositioning reflects strategic shifts following past controversies, focusing on specialty pharmaceuticals, eye health, and dermatology. This analysis examines Valeant’s current market positioning, core strengths, competitive landscape, and strategic prospects to inform investment and partnership decisions.

---

What Is Valeant’s Current Market Position?

Company Overview

Parameter	Details
Rebranding Year	2018
New Name	Bausch Health Companies Inc.
Revenue (2022)	$8.65 billion (approximate)
EBITDA Margin	~30%
Key Markets	North America (primary), Europe, and emerging markets
Core Segments	Ophthalmology, dermatology, gastrointestinal products, and branded generics

Market Share & Segments

Segment	Estimated Market Share (2022)	Main Products
Ophthalmology	~25-30%	Xalatan, Lumigan, Allergan's products
Dermatology	~15-20%	Aczone, Luzu, Sylant, various dermatology agents
Gastrointestinal & Other	~10%	Renvela, Relistor, other niche pharmaceuticals

Competitive Position

• Strength: Leading ophthalmology portfolio; diversified presence in dermatology and GI care.
• Weakness: Heavy reliance on mature product portfolios; lagging innovation pipeline compared to biotech rivals.
• Opportunities: Portfolio diversification through M&A; expansion into emerging markets.
• Threats: Patent cliffs, generic competition, regulatory scrutiny, and pricing pressures.

---

What Are the Core Strengths of Valeant (Bausch Health)?

1. Diversified Portfolio with Market Leaders

Product Category	Key Products	Market Share/Position	Strengths
Ophthalmology	Xalatan, Lumigan, B+L’s Allergan Assets	Leading global position in glaucoma & dry eye therapies	Established brand recognition, high-presence medical practitioners
Dermatology	Doxycycline-based Aczone, Luzu	Significant share in dermatological acne & fungal conditions	Recurring revenue streams, strong dermatologist relationships
Gastrointestinal & Others	Relistor, Reltez, Renvela	Niche but critical offerings	Essential medicines, strategic importance in markets

2. Strategic Acquisition & Asset Redeployment

Acquisition/Partnership	Year	Focus Area	Impact
Allergan’s Eye Care Assets	2019	Ophthalmology and aesthetic products	Strengthened market share, expanded R&D capabilities
Innovative R&D Collaborations	2020+	Ophthalmic device firms, biotech startups	Access to cutting-edge technologies, pipeline enhancement
RX Acquisition (e.g., Synergy)	2021	Specialty generics	Expanded portfolio, reduced patent risk

3. Cost Management & Operational Focus

• Streamlined supply chains post-restructuring.
• Focused on cost-effective manufacturing and procurement.
• Digital transformation initiatives for marketing, sales, and R&D.

---

What Is the Competitive Landscape Analysis?

Major Competitors & Market Dynamics

Competitor	Market Focus	Strengths	Weaknesses
Johnson & Johnson (J&J)	Ophthalmology, dermatology, consumer health	Diverse healthcare portfolio, strong R&D	Higher cost structure, slower decision-making
Novartis	Ophthalmology, generics, biosimilars	Innovation pipeline, global footprint	Patent expiration risks, integration challenges
Bausch + Lomb (FGL)	Vision care, ophthalmology	Strong brand in contact lenses and eye health	Limited diversification beyond vision care
Teva Pharmaceuticals	Generic pharmaceuticals, specialty medicines	Cost leadership, extensive global reach	Patent expirations, regulatory challenges

---

What Are Valeant’s Strategic Opportunities?

1. Focused Innovation & Pipeline Expansion

Strategy	Implementation	Expected Outcomes
Investment in R&D	Develop new ophthalmic and dermatological products	Strengthen patent-protected offerings, reduce generic reliance
Strategic M&A	Acquire niche biotechs or assets	Accelerate innovation, diversify revenue streams
Digital & Telehealth Integration	Develop remote diagnostics, AI-driven analytics	Improve R&D, clinical trial efficiency, market outreach

2. Geographic & Market Expansion

Initiative	Target Regions	Rationale
Emerging Markets Strategy	Latin America, Southeast Asia, Africa	Larger population base, growing healthcare investments
Direct Commercial Expansion	Europe, Asia-Pacific	Capture incremental market share, diversify revenue streams

3. Portfolio Optimization & Lifecycle Management

Approach	Actions	Benefits
Patent & Lifecycle Management	Litigation & settlement of patent disputes; repositioning products	Minimize patent cliff impacts, extend product life cycles
Divestment & Focus	Exit underperforming or non-core assets	Reallocate resources to high-growth segments

---

How Does Valeant’s Strategy Compare to Peers?

Dimension	Valeant (Bausch)	Johnson & Johnson	Novartis	Teva
Innovation Pipeline	Moderate, focus on pipeline expansion	Robust, biotech investments	Strong, bolstered by gene therapies	Less focus on R&D, cost-driven
Market Diversification	Moderate, focus on selected specialties	Highly diversified healthcare products	Focus on ophthalmology and generics	Generic-centric, cost-leader
M&A Activity	Selective, strategic acquisitions	Large, diversified M&A	Selective, strategic biotech deals	High, especially for cost reduction
Regulatory & Patent Strategy	Focused but vulnerable to patent cliffs	Advanced patent portfolio	Aggressive innovation, patent filings	Focus on cost and patent life extension

---

FAQs

1. How has Valeant’s rebranding affected its market position?

Post-rebranding to Bausch Health in 2018, the company aimed to repair reputation and refocus on core strengths. While initial growth slowed, improved transparency and strategic acquisitions have stabilized revenue, especially in ophthalmology and dermatology.

2. What are the primary risks facing Valeant’s competitive position?

• Patent expiries undermining legacy products
• Increased generic competition
• Regulatory scrutiny following past controversies
• Pricing pressures in major markets
• Slower innovation pipeline compared to biotech peers

3. How does Valeant’s innovation pipeline compare with peers?

Valeant’s pipeline is moderate; it relies heavily on existing assets rather than breakthrough innovation, unlike Novartis or J&J, which invest heavily in R&D and emerging therapies.

4. What M&A opportunities are most aligned with Valeant’s strategic priorities?

Acquisitions in biotech or niche pharmaceutical companies with innovative ophthalmic or dermatological therapies are prioritized, to bolster patent portfolios and diversify revenue.

5. How significant is Valeant’s presence in emerging markets?

While historically concentrated in North America and Europe, recent efforts focus on expanding into Latin America, Asia-Pacific, and Africa, offering high growth but requiring tailored market strategies.

---

Key Takeaways

• Market Position: Valeant (Bausch) maintains a leading role in ophthalmology and dermatology, supported by strong brand portfolios and strategic M&A.
• Strengths: Diversified product offerings, significant market share, strategic acquisitions, operational efficiency.
• Weaknesses: Heavy reliance on mature portfolios, exposure to patent cliffs, past reputation challenges.
• Opportunities: Innovation pipeline expansion, geographical diversification, lifecycle management, digital health integrations.
• Threats: Conventional and generic competition, regulatory risks, market price pressures.
• Strategic Recommendations: Pursue targeted biotech acquisitions, invest in R&D for new therapies, expand footprint in emerging markets, and continue lifecycle management.

---

References

1. Bausch Health Companies Inc. Annual Report 2022.
2. IQVIA Market Reports 2022.
3. Reuters: Valeant Rebranding and Strategic Shift.
4. ClinicalTrials.gov: Current Valeant/Bausch Pipeline Accessed 2023.
5. McKinsey & Company: Pharma Industry Competitive Strategies 2022.

---

This report aims to support strategic investment, partnership considerations, and competitive positioning assessments within the pharmaceutical landscape, emphasizing Valeant’s evolving market stance.